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Abstract: Background: Periodontitis is a chronic inflammatory disease, which affects the supporting 
tissues of the teeth, and without proper treatment it may lead to tooth loss. Antibiotics - administered 
orally - have been widely used in the treatment of periodontitis. With the conventional administration 
routes, adequate drug levels cannot be reached in the periodontal pockets and oral application of antim-
icrobials could lead to side effects. Drug delivery systems containing antibiotics, administered at the 
site of infection, could possibly help eliminate pathogen bacteria and treat periodontitis.  
Objective: The aim of the recent study was to create a locally swellable, biodegradable, biocompatible, 
mucoadhesive, lipophilic drug delivery system (SDLDDS) containing antimicrobial drugs which sof-
tens at body temperature, accommodate to the shape of the periodontal pocket and can provide extended 
drug release for at least one week.  
Methods: During the formulation, thermoanalytical, consistency, wettability, swelling, degradation and 
drug release studies were applied to determine the ideal ratios of lipid bases, structure-building compo-
nents and surface active agent concentrations.  
Results and Discussion: The structure-building component cetostearyl alcohol appeared to be the most 
convenient, thanks to its wettability and mechanical properties, which led to controlled drug release. 
With the use of ideal concentrations of components (10% surfactant, 40% structure-building compo-
nent, 32 % lipid base, 15% antimicrobial agent and 3% polymer), sustained drug release can be pro-
vided up to nearly 3 weeks. 
Keywords: lipid drug delivery, sustained drug release, swelling, degradation, periodontitis, periodontal pocket, antimicrobial 
therapy. 
1. INTRODUCTION 
 Periodontitis (PD) is a chronic inflammatory disease, 
which affects the supporting tissues of the teeth, and without 
proper treatment it may lead to tooth loss [1, 2]. Periodontal 
diseases are multifactorial diseases: initiation and progres-
sion of periodontitis require the simultaneous occurrence of 
virulent periodontal pathogen microorganisms, local envi-
ronment, host susceptibility, genetic and acquired risk fac-
tors. The subgingival biofilm initiates and maintains inflam-
matory responses in the periodontal tissues and periodonto-
pathogen microorganisms also play a role directly in tissue 
damage through different virulence factors [3-5]. Inflamma-
tion is mostly caused by a wide set of microorganisms  
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(viruses, bacteria, etc.), with the most important putative 
pathogens being Gram-negative bacteria, namely Aggregati-
bacter actinomycetemcomitans, Porphyromonas gingivalis, 
Tannerella forsythia and Treponema denticola, but other 
species are also considered to be responsible for disease ini-
tiation and progression [6]. 
 The disease is characterised by the destruction of the gin-
gival tissues, the resorption of the alveolar bone, the migra-
tion of the junctional epithelium in the direction of the roots 
and the formation of a so-called periodontal pocket (PP) [2]. 
This subgingival area is ideal for the proliferation of anaero-
bic pathogen bacteria, some of which were listed above, 
which activate neutral degrading enzymes, thereby causing a 
vicious cycle [2, 6]. 
 The oral cavity and PPs have all the important features 
required to be an appropriate medium for the growth and 
maturation of a bacterial biofilm [6]. A community of bacte-
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rial cells producing a polymeric matrix in which they are 
enclosed on a surface is called a bacterial biofilm [7]. As 
there are lipids, saccharides in the nutrients and proteins and 
glycoproteins in saliva, bacteria have access to adequate 
nourishment [6]. 
 As biofilm formation and adherence to tooth surface are 
the main causes of periodontal disease, the removal of 
plaque and the eradication of microorganisms are key ele-
ments of an effective therapy [8-10]. The most common 
methods of mechanical debridement are scaling and root 
planing with some limitations, such as the inability to access 
ecological niches. The varying geometry of deep pockets, the 
irregularities of the root surface, root furcations, concavities 
and infected pocket walls are not accessible to mechanical 
removal by hand or with power-driven instruments [11]. 
Because of the imperfect removal of the bacterial biofilm 
and the high number of pathogen microorganisms present in 
the oral cavity, chances are high that the remaining microbi-
ota recolonises the subgingival area [12].  
 The infectious nature of periodontitis indicates an adjunc-
tive anti-infective chemotherapy to eradicate or reduce the 
amounts of pathogenic bacteria from ecological niches. Our 
current understanding of antimicrobial therapy requires the 
disruption of the structured biofilm by mechanical debride-
ment before antimicrobial therapy is considered [11]. 
 Antibiotics have been widely used in the treatment of PD 
and can help eliminate the oral pathogens responsible for the 
formation of the disease. However, with conventional ad-
ministration routes (e.g. per os), adequate drug levels are not 
reachable in the PPs even with high systemic concentrations. 
The oral application of high doses of antimicrobial agents 
leads to serious side effects with limited efficacy [13]. 
 As the peroral application of antimicrobial drugs is not a 
viable option, antimicrobial local drug delivery systems ap-
plied at the inflammation site could be a possibility in the 
elimination of pathogen bacteria and in the treatment of PD. 
Numerous articles demonstrated various types of local drug 
delivery systems with different active agents directed at PD 
[1, 2, 12-25]. Applicable active substances could be chlor-
hexidine, metronidazole, tetracyclines, clindamycin, oflox-
acin [2], moxifloxacin [17], amoxicillin [18] or even povi-
done iodine [26]. 
 The development of local, targeted, sustained and con-
trolled release therapeutic systems containing different active 
agents are among the hot topics of pharmaceutical research. 
Serious adverse effects of particular drugs can be prevented 
by their administration, and even a continuous effect could 
be obtained without sequential dosage and therapeutic drug 
levels can be achieved at the desired place. Different nano 
carriers [27], layered structures [22, 28], polymer matrixes 
[27, 29] and lipid systems [30, 31] may be used to achieve 
these features. 
 Sustained or controlled release of drugs can be also ob-
tained with the use of different vehicles like polymers or 
other materials capable of up-building a coherent structure 
[28, 32-34]. 
 The aim of the recent study was to create a locally swel-
lable, degradable, lipophilic drug delivery system 
(SDLDDS) containing an antimicrobial drug, which softens 
at body temperature, accommodates to the shape of the PP, is 
biodegradable, biocompatible, can provide extended drug 
release at least for one week and has a mucoadhesive feature. 
2. MATERIALS AND METHODS 
2.1. Materials 
 For the compositions Suppocire BP (SBP) pellets (Gatte-
fossé, Saint-Priest, France), Methocel E4M (Colorcon Ltd., 
Dartford, United Kingdom), Kolliphor RH40 (KP) (BASF 
ChemTrade GmbH, Ludwigshafen, Germany), amoxicillin 
(AMX) (Antibióticos de León S.L.U., León, Spain), white 
beeswax (WB), cetostearyl alcohol (CA) and metronidazole 
(MZ) (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary) 
were used. 
 During the drug release tests, a simulated saliva solution 
was used as an acceptor phase. The composition of the solu-
tion was the following: 0.720 g/L potassium chloride, 0.600 
g/L sodium chloride, 0.030 g/L citric acid (Ph. Eur. 8., Hun-
garopharma Plc., Budapest, Hungary), 0.220 g/L calcium 
chloride dihydrate, 0.680 g/L potassium phosphate mono-
basic, 0.866 g/L sodium phosphate dodecahydrate, dibasic, 
1.500 g/L potassium bicarbonate and 0.060 g/L potassium 
thiocyanate (Ph. Eur. 8., Molar Chemicals Ltd., Halásztelek, 
Hungary) at a pH of 6.5 [35]. For wettability, swelling and 
degradation measurements purified water was used. 
 The preliminary microbiological investigations were im-





), a facultatively anaerobic, oral 
streptococcus. Bacterial suspensions were made in 0.9% 
NaCl solution. Columbia agar plates with 5% of horse blood 
were used as culture media. 
2.2. Composition of the Local Drug Delivery Systems 
 Five main components were used to create the delivery 
systems. A lipophilic component SBP was chosen as the 
lipid base and CA or WB was used as a structure-building 
component. All of the lipid components can be safely used 
on mucosae, where the SBP can soften at body temperature. 
Each structure-building component was used in four differ-
ent concentrations, from which the best was chosen accord-
ing to the results of different measurements. 
 KP was used as a surface active agent, which helps the 
wetting of the formulation in the PP and thus, promotes its 
swelling and degradation. Different concentrations were ap-
plied to decide which is the most suitable for the delivery 
system. 
 Methocel E4M (HPMC) was used as a swelling and 
bioadhesive agent. 
 AMX or MZ, which are often used in PD treatment, were 
incorporated into the vehicles. 
 All of the formulations were created by melting. At first, 
the two lipophilic components and the surfactant were melted 
together at 70 °C on a hot plate (IKA-WERKE RCT B, ETS-
D4, IKA Werke GmbH & Co. KG, Staufen im Breisgau, 
Germany), then the polymer was added and homogenized with 
an overhead stirrer at 50 RPM (Digital Overhead Stirrer - 
DLH, VELP Scientifica, Usmate Velate, Italy). The antimi-
crobial agent was only added right before moulding to avoid 
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its possible thermal decomposition. Delivery systems were 
created by moulding the melted formulations into a round 
shaped mould 1.5 mm in thickness and 9 mm in diameter. 
 The optimal ratio of the ingredients was determined by 
various methods described below. Before any measurement, 
the formulations were kept at room temperature in a desicca-
tor for at least 24 h to reach complete solidification. 
 The compositions of different formulations examined 
during our study can be found in Table 1. The course of the 
investigations is shown in Fig. (1). 
2.3. Differential Scanning Calorimetry (DSC) Measure-
ments 
 DSC measurements were used to determine the softening 
temperature and the effect of the structure-building compo-
nent on the melting point and the structure. All of the meas-
urements were done with a Mettler-Toledo DSC 821
e
 in-
strument in argon atmosphere (100 mL/min) between + 10 
and 100 °C raising the temperature by 5 °C per minute. 10 
mg of the samples were placed into 40-L aluminium pans. 
The pans were sealed and holed on top. 
 
Table 1. The composition of formulations analysed with different methods. 
Concentration of the Components (%) 
Structure-building 
Component 
Lipid Base Surfactant Polymer Antimicrobials Measurements 
WB CA SBP KP Methocel E4M MZ AMX 
10 0 85 5 0 0 0 
10 0 80 10 0 0 0 
10 0 75 15 0 0 0 
10 0 70 20 0 0 0 
0 5 90 5 0 0 0 
0 5 85 10 0 0 0 
0 5 80 15 0 0 0 
0 5 75 20 0 0 0 
20 0 67 10 3 0 0 
40 0 47 10 3 0 0 
60 0 27 10 3 0 0 
0 20 67 10 3 0 0 




0 60 27 10 3 0 0 
20 0 67 10 3 0 0 
40 0 47 10 3 0 0 
60 0 27 10 3 0 0 
0 20 67 10 3 0 0 
0 40 47 10 3 0 0 
Swelling and degradation 
0 60 27 10 3 0 0 
20 0 57 10 3 10 0 
40 0 37 10 3 10 0 
60 0 17 10 3 10 0 
0 20 57 10 3 10 0 
0 40 37 10 3 10 0 
0 60 17 10 3 10 0 
0 20 57 10 3 0 10 
0 40 37 10 3 0 10 
Drug release study 
0 60 17 10 3 0 10 
0 40 42 10 3 0 5 
0 40 37 10 3 0 10 
Preliminary microbiological 
study 
0 40 32 10 3 0 15 
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Fig. (1). Flowchart showing the course of the investigations. 
2.4. Wettability of the Delivery Systems 
 The wettability of the formulations was studied with an 
OCA Contact Angle System (Dataphysics OCA 20, Data-
physics Inc., GmbH, Germany). As a flat surface is needed 
for optical contact angle measurements to be carried out, 
microscopic slides were covered with the melted formula-
tions (without active ingredients). After moulding, they were 
stored at room temperature in a desiccator for 24 h. The de-
gree of wetting was determined by measuring the contact 
angle: 10 μL of water from a calibrated syringe was dripped 
on the surface of the formulations moulded onto the micro-
scopic slides, and the contact angle of the water droplets and 
the formulations was measured by computer software. 
2.5. Determination of Consistency by Penetrometry 
 The consistency of the different formulations was deter-
mined with a penetrometer (07/2008:20909, 2.9.9, 2.9.9.-1,-
3., Ph. Eur. 8) by measuring the penetration depth of a pene-
trating object into the test samples. Melted samples were 
poured into Petri dishes, and they were stored at room tem-
perature for 24 h in a desiccator to reach the total solidifica-
tion. Five parallel measurements were carried out with each 
sample at room temperature. The penetration depth was 
measured for one minute. The penetration depth directly 
refers to the consistency of the samples. 
2.6. Swelling and Degradation 
 The water absorption capacity of the formulations was 
determined gravimetrically in order to examine the effects of 
the incorporated polymer on the swelling and degradation 
properties of the delivery systems. At first, the formulations 
were weighed with an analytical scale then were immersed 
into 10 mL of distilled water and were thermostated at 37°C 
for various periods of time (1, 1.5, 2, 3, 4, 5, 6, 7 and 14 
days). After the defined time periods, they were weighed 
again. After the second measurement, the formulations were 
held at room temperature until they totally dried out, and 
they were weighed again for a third time. With the results, 
the absorption capacity and the swelling related degradation 
could be determined. 
2.7. Drug Release Study 
 The in vitro drug release profiles of the formulations 
were determined. The compositions were weighed with an 
analytical scale and put in 5-cm-long dialysis tubes (Spec-
tra/Por
®
 Standard RC tubing, MWCO: 12-14 kD) and sealed 
with closures. The tubes containing the formulations were 
placed in 50 mL of acceptor phase thermostated at 37 °C. As 
an acceptor phase, a simulated saliva solution was used. 
Drug release was investigated for 48 h and 3 parallel meas-
urements were carried out. 5 mL of samples were taken (at 
0.5, 1, 4, 8, 12, 24, 36, 48 hours) and were replaced with 5 
mL of acceptor phase. The released drug, AMX and MZ, 
was quantified by UV spectrophotometry (Helios  Ther-
mospectronic UV-spectrophotometer v4.55, Unicam: 
Thermo Fisher Scientific, Waltham, MA) at 273 and 318 nm, 
respectively. 
2.8. Investigation of Sustained Antimicrobial Effect: Pre-
liminary Study 
 A preliminary microbiological study was conducted in 
order to measure the antibacterial effectiveness of the devel-
oped formulations. As a typical oral bacterium, Streptococ-
cus mutans control strain was used. A 0.5 McFarland stan-
dard concentration bacterial suspension was made with 0.9% 
NaCl solution (in suspension it is equivalent to approxi-
mately 1.5108 colony forming units/mL). The suspension 
was spread onto a horse blood agar plate, then formulations 
containing 5, 10 and 15 m/m % of AMX were placed on it. 
After 24 hours of incubation in 5% CO2 atmosphere, the di-
ameter of the inhibition zones was measured. The formula-
tions were then put on a new horse blood agar plate, also 
inoculated with 0.5 McFarland standard concentration 
freshly made bacterial suspension of Streptococcus mutans. 
The plates were then put in 5% CO2 atmosphere for 24 
hours. This was repeated until no inhibition zone could be 
detected. 
2.9. Statistical Analysis 
 The results of the drug release measurements were ana-
lysed statistically with GraphPad Prism version 5 software, 
using two-way ANOVA analysis with Bonferroni post-tests. 
A level of p0.05 was considered significant, p0.01, very 
significant, and p0.001 highly significant. 
3. RESULTS AND DISCUSSION 
3.1. Differential Scanning Calorimetry (DSC) Measure-
ments 
 DSC was used to determine the concentration of the 
structure-building component and the softening temperature 
of the formulations. 
 One of the structure-building components is white bees-
wax, which is natural beeswax but chemically bleached. It 
consists of esters of C24 to C36 straight-chain alcohols and 
straight-chain acids. It is used in creams, oils, ointments to 
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increase consistency and in emulsions as a stabilizer. Ac-
cording to the literature, its melting point is between 60-67 
°C [36]. In our investigation, DSC measurements show an 
endothermic peak at 64.45 °C (Fig. 2). 
 The other type of structure-building component is ce-
tostearyl alcohol, which is a mixture of solid alcohols and 
consists of mainly stearyl and cetyl alcohols. It is mostly 
used in semisolids as a surfactant, a co-surfactant or as a 
viscosity increasing agent. In oral dosage forms it may slow 
the dissolution. The specific melting range of the substance 
is between 48-56 °C [36]. According to our DSC measure-
ments, it is 56.61 °C (Fig. 2).  
 Kolliphor RH40 is a polyoxyethylene 40 castor oil de-
rivative. It can be used as an emulsifying or wetting agent. 
According to the literature [36] and the DSC measurements, 
it has a congealing temperature at 16-26 °C, and a melting 
point approximately at 30 °C (Fig. 2). 
 Suppocire BP was used as the lipophilic base of the sys-
tems. It has a melting range between 36-37 °C and a hy-
droxyl value between 30 and 50. Mostly, it is used as a base 
for suppositories [36]. According to our measurements, it has 
a melting point at 39.08 °C (Fig. 2). 
 Our results show that the softening temperature of the 
systems meets our expectations as all of the systems soften 
partially between 34-36 °C, which is slightly lower than the 
average body temperature in the oral cavity (Fig. 2), result-
ing in adaptation to the geometry of PPs. 
 Firstly, we evaluated how the concentration of the sur-
face active agent affects the melting point of the composi-
tions. The concentration of the structure-building component 
was fixed (WB at 10 m/m % or CA at 5 m/m %). The effect 
of the increasing quantity of the surface active agent (from 5 
m/m % to 20 m/m %) on the melting point was examined. 
The graphs (Figs. 2 and 3) clearly show that the specific en-
dothermic peak at the melting point of the structure-building 
component (WB: 64.45 °C, CA: 56.61 °C) cannot be seen, 
which means that in this concentration range the structure-
building components are incorporated homogeneously into 
the structure instead of the formation of a separated crystal-
line structure. Besides this, the 37°C melting point of SBP 
decreases and the sharp peak at 37°C broadens in the direc-
tion of lower temperatures, but the melting point stays above 
35°C. 
 Following this, the effect of the concentration of the 
structure-building component on the thermal behaviour of 
the formulations was evaluated. In this case, the concentra-
tion of the surface active agent was held at the mean value of 
10 m/m %, while the concentration of the structure-building 
component was changed from 5 m/m % (CA) or 10 m/m % 
(WB) to 20, 40 and 60 m/m %. It can be seen clearly that 
with the increasing concentration of the structure-building 
component, another peak appears above the temperature of 
40 °C, which corresponds to the melting point of waxes, but 
it is lower than the melting point of the pure material. The 
peak at the melting point of SBP shifted to lower tempera-
tures when the concentration of the structure-building com-
ponent was increased to 20 m/m % and shifted to higher 
temperatures when it was changed to 40 or 60 m/m %. (Figs. 
4 and 5). 
 
Fig. (2). DSC curves of pure Suppocire BP, white beeswax and 
Kolliphor RH40 and the compositions containing 10 m/m % white 
beeswax and 5, 10, 15 and 20 m/m % of surface active agent. 
 
 
Fig. (3). DSC curves of pure Suppocire BP, cetostearyl alcohol, 
Kolliphor RH40 and the compositions containing 5 m/m % ce-
tostearyl alcohol, 5, 10, 15 and 20 m/m % of surface active agent. 
 
 The DSC results (Figs. 4 and 5) clearly show that for 
formulations containing 20 m/m % of structure-building 
component there is no separate peak of the base and the 
structure building component, which will result in total melt-
ing at body temperature and sustained drug release probably 
cannot be reached thanks to the disintegration of the melted 
formulation. 
 The compositions containing 40 and 60 m/m % of the 
structure-building component show different results. The 
peaks of the structure-building component and the lipid base 
are separate, thus there is a compound with a lower melting 
point and another with a higher one (Figs. 4 and 5) From this 
it can be concluded that the system has a part which will 
melt or soften at body temperature, and another part which 
will give a structure to the system even at body temperature, 
thereby hindering disintegration and fast degradation. 
3.2. Wettability of the Delivery Systems 
 As the systems are mostly hydrophobic, a surface active 
agent is needed to help the wetting of the  delivery  systems  
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Fig. (4). DSC curves of pure Suppocire BP, white beeswax and 
Kolliphor RH40 and the compositions containing different concen-




Fig. (5). DSC curves of pure Suppocire BP, cetostearyl alcohol and 
Kolliphor RH40 and the compositions containing different concen-
trations (20, 40 and 60 m/m %) of structure-building component 
(cetostearyl alcohol). 
 
with exudates in PPs, which is critical to the swelling of the 
preparations and consequently to drug release. Good wetting 
contributes to the degradation and elimination of the systems 
from the PP. An optical contact angle measurement system 
was used to determine the wettability of our systems. 
 First, we evaluated the effect of various concentrations of 
the surface active agent (5, 10, 15 and 20 m/m %), then we 
measured the effect of the structure-building components 
with constant surfactant concentrations. 
 In case of beeswax and the varying concentrations of 
surface active agent, the higher concentrations of surfactant 
decreased the contact angle, which means the wetting prop-
erties of the delivery systems became better. There is no re-
markable difference between the preparations containing 10, 
15 and 20 m/m % of surface active agent (Table 2). Based on 
the results of formulations containing WB, the best is the 10 
m/m % concentration of surface active agent as the same 
wettability can be reached with higher amounts of wetting 
agent. 
 The evaluation of the results of the drug delivery systems 
containing CA as a structure-building component showed 
that the formulation with the best wettability was the one 
with 20 m/m % of surfactant (Table 2). Contact angles had a 
max. value at 15 m/m % of surface active agent, but the dif-
ferences between the various compositions were not remark-
able so the 10 m/m % of surfactant was chosen. All of the 
formulations made with CA (except the one with the 15 m/m 
% of surfactant) had better wettability than the preparations 
containing WB. 
 The effect of the different concentrations of the structure-
building component on the wettability of the preparations 
was measured. The concentration of the wetting agent was 
held at a 10 m/m % value (Table 3). 
 Increasing concentrations of WB increased wettability as 
the contact angle was smaller. The same is not applicable to 
the formulations containing CA. The contact angle increases 
with increasing the CA concentration (Table 3). 
3.3. Determination of Consistency by Penetrometry 
 The consistency of the formulations was measured by 
penetrometry. The penetration depth of a penetrating object 
into a test sample was measured. From penetration depth 
consistency can be calculated or it directly refers to the con-
sistency of the samples. The effect of the surface active agent 
and the structure-building component on consistency was 
evaluated. 
Table 2. Average and SD of contact angles of compositions, made with white beeswax or cetostearyl alcohol, containing different 
concentrations (5, 10, 15 and 20 m/m %) of surface active agent. 
Contact angle (°) 
Concentration of KP (%) 
WB CA 
 Average SD Average SD 
5 94.63 1.63 66.81 3.20 
10 98.04 4.10 75.44 8.72 
15 98.33 1.32 102.24 1.63 
20 100.86 0.65 58.29 6.12 
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 Formulations made with CA were harder as penetration 
into the test objects was smaller. The concentration of the 
surface active agent had a small effect on penetration depth 
and consistency. The increasing concentration of KP caused 
deeper penetration into the penetrating objects except for the 
preparations made with CA containing 15 m/m % and 20 
m/m % of KP, where the penetration depth was 0.03 mm 
deeper when measuring the system with a smaller quantity of 
surface active agent (Table 4). 
 As the surfactant concentration had not influenced the 
penetration depth remarkably, in accordance with the DSC 
and wettability results the formulations with 10 m/m % of 
surface active agent was chosen to carry out the further in-
vestigations. 
 The penetration depth into preparations made with differ-
ent concentrations of structure-building component was also 
evaluated. The concentration of the surface active agent was 
held at a constant 10 m/m % value. The increasing quantity 
of the structure-building component in case of both WB and 
CA made the formulations harder and the penetration depth 
shallower. CA had a greater impact on penetration depth and 
consistency than WB because 40 and 60 m/m % concentra-
tions showed a higher decrease in penetration depth (Table 
5). 
 The formulations containing CA have better wettability 
and solidity, which may influence not only the application of 
the system but also drug release. 
3.4. Swelling and Degradation 
 The swelling and degradation properties of formulations 
containing 20, 40 and 60 m/m % of CA were measured gra-
vimetrically to determine whether the preparations are able 
to absorb water, swell and degrade. Degradation is necessary 
as the systems are aimed to be biodegradable and to be 
eliminated from the subgingival area. 
 The formulations containing 20 m/m % of structure-
building component fell apart on the first day of measure-
ment. In light of this, the results connected to 20 m/m % of 
CA are not shown in the figures. 
 Fig. (6) shows the swelling ratio of the formulations con-
taining 40 and 60 m/m % of CA. 
 Swelling ratio was calculated as follows: 
           (1) 
where  is the mass of the formulations after immersed in 
water for the specified time and  is the mass of the dried 
formulations. 
 The results show that the preparations containing 40 m/m 
% of structure-building component can absorb more water as 
they are not as hard as the formulations containing 60 m/m 
% of CA (Fig. 6). 
 Swelling lasts for four days, then the swelling ratio re-
mains on the same level. This may happen because a balance 
is formed between swelling and degradation (Fig. 6). 
Table 3. Average and SD of contact angles of compositions containing different concentrations of the structure-building compo-
nents (white beeswax or cetostearyl alcohol) compared to compositions with a lower quantity of structure-building com-
ponent. 
Contact Angle (°) 
WB CA 
Concentration of the Structure-building 
Component (%) 
Average SD Average SD 
20 91.80 7.53 46.60 7.19 
40 76.27 11.12 60.95 4.15 
60 74.30 7.65 69.16 1.71 
 
Table 4. Average and SD of penetration into compositions, made with white beeswax or cetostearyl alcohol, containing different 
concentrations (5, 10, 15 and 20 m/m %) of surface active agent. 
Penetration Depth (mm) 
WB CA Concentration of KP (%) 
Average SD Average SD 
5 5.63 0.25 4.34 0.07 
10 5.76 0.34 4.54 0.11 
15 5.79 0.27 4.87 0.20 
20 6.54 0.27 4.84 0.26 
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Fig. (6). Swelling ratio of compositions containing 40 and 60 m/m 
% of cetostearyl alcohol.  40 m/m %,  60 m/m % of cetostearyl 
alcohol. 
 
 Degradation (%) was calculated from the following equa-
tion: 
          (2) 
where mo is the mass of the original formulations and md is 
the mass of the dried formulation after the swelling and deg-
radation measurements. 
 Degradation properties show no remarkable differences 
between the two concentrations. Similarly to swelling, the 
increase of degradation stops on the fourth day as a possible 
result of a balance between swelling and degradation (Fig. 7). 
3.5. Drug Release Study 
 Drug release measurements were performed to investi-
gate the possibility of achieving the sustained release of ac-
tive agents by using increasing concentrations of the struc-
ture-building component. Both of the structure-building 
agents were tested. The drug release of two different antimi-
crobials (amoxicillin and metronidazole) was evaluated from 
the compositions. 
 AMX is a semi-synthetic penicillin derivative, with a 
broad spectrum of antibiotic activity against aerobic or an-
aerobic Gram-positive and Gram-negative bacteria [18, 37]. 
 
Fig. (7). Degradation of compositions containing 40 and 60 m/m % 
of cetostearyl alcohol.  40 m/m %,  60 m/m % cetostearyl alco-
hol. 
 
 MZ is an antibacterial agent, belonging to the nitroimida-
zole group. It is known to be effective against numerous bac-
teria and protozoa, including anaerobes [2, 38]. 
 MZ and AMX are also used in the therapy of periodontal 
disease as an adjunct to the mechanical debridement (scaling, 
root planing) locally or systematically [39].  
 Six different compositions were measured and with every 
composition 3 parallel measurements were carried out. The 
release of MZ was investigated from systems made with WB 
and CA. AMX release was only tested for preparations with 
CA due to the results of MZ release. The formulations con-
tained: SBP, Methocel E4M, KP, 20, 40 and 60 m/m % of 
WB or CA, 10 m/m % of AMX or MZ. 
 The results of the evaluation of MZ release from formu-
lations containing 20, 40 and 60 m/m % of WB showed large 
SD values. This may be due to the fact that the compositions 
fell apart during the drug release tests. It can be concluded 
that WB is unsuitable for providing the sustained release of 
antimicrobial agents, so because of this AMX release was 
measured only from formulations made with CA. 
 The results show that, with increasing concentrations of 
CA, it is possible to prolong the MZ release from the formu-
lations (Fig. 8). Fig. (8) shows  that  formulations  containing  
Table 5. Average and SD of penetration into compositions containing different concentrations of the structure-building compo-
nents (white beeswax or cetostearyl alcohol) compared to compositions with a lower quantity of structure-building com-
ponent. 
Penetration Depth (mm) 
WB CA 
Concentration of the Structure-building 
Component (%) 
Average SD Average SD 
20 4.85 0.12 4.95 0.26 
40 4.35 0.15 3.17 0.27 
60 3.60 0.23 1.87 0.09 
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Fig. (8). Release of metronidazole from formulations containing 
different concentrations (20, 40 and 60 m/m %) of cetostearyl alco-
hol.  20 m/m %,  40 m/m %,  60 m/m % cetostearyl alcohol. 
Drug release from compositions containing 40 and 60 m/m % ce-
tostearyl alcohol shows highly significant difference (***) com-
pared to formulations with 20 m/m % cetostearyl alcohol at 4, 8 and 
12 hours. 
 
20 m/m % of CA have a faster drug release than the formula-
tions made with 40 or 60 m/m % of CA, which can be ex-
plained by the faster degradation of formulations containing 
20 m/m % CA during the drug release measurements. There 
is no significant difference between the systems containing 
40 or 60 m/m % of structure-building components. 
 AMX release from formulations made with CA was simi-
lar to the release of MZ as it was possible to sustain the 
AMX release. Another similarity to MZ release is that there 
is no significant difference between the release of AMX 
from formulations made with 40 m/m % and 60 m/m % CA 
(Fig. 9). 
 The drug release mechanism can be characterized with 
the following equation: 
            (3) 
where  is the fraction of drug released, k is the kinetic 
constant and n is the release exponent describing the mecha-
nism of the release [40]. 
 
Fig. (9). Release of amoxicillin from formulations containing dif-
ferent concentrations (20, 40 and 60 m/m %) of cetostearyl alcohol. 
 20 m/m %,  40 m/m %,  60 m/m % cetostearyl alcohol. Drug 
release from compositions containing 40 m/m % cetostearyl alcohol 
shows significant difference at (*) at 8 hours compared to formula-
tions with 20 m/m % cetostearyl alcohol. The drug release from 
compositions containing 60 m/m % cetostearyl alcohol also shows 
significant difference (*) at 8 and 12 hours compared to formula-
tions with 20 m/m % cetostearyl alcohol. 
 
 These values were determined from the equation of drug 
release curves (Table 6). 
3.6. Investigation of Sustained Antimicrobial Effect: Pre-
liminary Study 
 A preliminary microbiological study was made to inves-
tigate the sustained microbiological activity of our formula-
tions containing 5, 10 and 15 m/m % of AMX. The results 
are in Table 7. The diameter of the inhibition zone was 
measured in mm and it is the average of two perpendicular 
diameters. The averages were rounded to integer numbers. 
 AMX containing systems inhibited bacterial growth for 8 
to 21 days. 
 With 5 m/m % of AMX incorporated into the systems, 
growth inhibition lasted for 8 days. 10 m/m % of AMX caused 
a 10-day growth inhibition, while the 15 m/m % one lasted for 
21 days. The inhibition zone of the 15 m/m % AMX contain-
Table 6. Release exponent (n) and kinetic constant (k) at different structure-building component concentrations of formulations 
containing amoxicillin or metronidazole and the R
2
 values of the fitted curves. 
Active Ingredient 
Structure-building Component  




20 0.5560 15.169 0,9598 
40 0.8717 4.5846 0,9853 MZ 
60 0.8808 4.4657 0,9866 
20 0,8503 5,4502 0,9416 
40 0,9264 3,1313 0,9721 AMX 
60 0,8457 4,1243 0,9955 
10    Current Drug Delivery, 2018, Vol. 15, No. 0 Léber et al. 
ing formulation could not be measured after 24 h as there was 
no detectable growth of the bacteria in the Petri dish. The larg-
est measurable inhibition zone was 60 mm in diameter and 
was smaller and smaller day by day (Table 7). 
 The shrinking zones are the signs of the decreasing con-
centrations of the active ingredient in the formulations as the 
systems were put on a new plate in every 24 h. 
 During the microbiological evaluation all of the formula-
tions absorbed water, swelled. Water absorption and swelling 
are necessary for drug release. 
 The prolonged antibacterial effect means that our deliv-
ery system is ready to sustain the AMX release (Table 7). 
CONCLUSION 
 By developing lipid formulations, anhydrous drug deliv-
ery systems could be prepared which soften at body tempera-
ture, therefore they fit the geometry of the periodontal pock-
ets. Wettability is provided by the added surface active 
agent, while the softening at body temperature is due to the 
low melting point of the lipid components (35-37 °C). Sus-
tained drug release is supported by the structure-building 
components. 
 According to the wettability measurements, the 10 m/m 
% Kolliphor RH40 concentration is optimal. The type and 
the concentration of the structure-building component highly 
influence hardness and - under 40 m/m % - drug release. The 
results of penetrometry, the swelling, degradation and drug 
release measurements indicate that the optimal structure-
building component is CA in 40 m/m %. In this composition 
the formula softens at body temperature and prolonged drug 
release can be ensured as well. Sustained drug release was 
also confirmed with a preliminary antimicrobial test. 
 In our work, we formulated a subgingival, swellable, 
biodegradable drug delivery system, which could provide 
sustained antimicrobial activity up to almost 3 weeks. 
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